NCT Number: NCT04221542
Patient Summary
Phase: PHASE1
Trial Summary: Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D). – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Amgen
Acronym:
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives